Takara Bio Dirección

Dirección controles de criterios 2/4

El CEO de Takara Bio's es Koichi Nakao, nombrado en May 2009, tiene una permanencia de 15.08 años. posee directamente un 0.06% de las acciones de la empresa, con un valor de ¥73.96M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 5.5 años, respectivamente.

Información clave

Koichi Nakao

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	15.1yrs
Participación del CEO	0.06%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Koichi Nakao (62 yo)

15.1yrs

Permanencia

Mr. Koichi Nakao was Director & President of Takara Bio Inc. from May 2009 to April 2020. Mr. Nakao was Director of Takara Bio Inc. from April 2002 to May 2009. Mr. Koichi Nakao is CEO, President & Represe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Koichi Nakao	CEO, President & Representative Director	15.1yrs	sin datos	0.060% ¥ 76.3m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	2.4yrs	sin datos	0.014% ¥ 18.0m
Tsuyoshi Miyamura	Senior Managing Director & Director	10yrs	sin datos	0.010% ¥ 12.8m
Junichi Mineno	VP, Executive Officer & Director	2.4yrs	sin datos	0.012% ¥ 15.3m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	7yrs	sin datos	0.0025% ¥ 3.2m
Andrew Farmer	Head of Research and Development	no data	sin datos	sin datos
Akira Kodera	Managing Executive Officer	1.4yrs	sin datos	sin datos
Kyoko Nakajima	Managing Executive Officer	1.4yrs	sin datos	sin datos
Nukaya Ikuei	Executive Officer	less than a year	sin datos	sin datos
Ikuei Nukaya	Managing Executive Officer	less than a year	sin datos	sin datos

2.4yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4974 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Koichi Nakao	CEO, President & Representative Director	22.2yrs	sin datos	0.060% ¥ 76.3m
Yoh Hamaoka	CFO, Senior Executive Officer & Director	3yrs	sin datos	0.014% ¥ 18.0m
Tsuyoshi Miyamura	Senior Managing Director & Director	6yrs	sin datos	0.010% ¥ 12.8m
Junichi Mineno	VP, Executive Officer & Director	10yrs	sin datos	0.012% ¥ 15.3m
Katsuhiko Kusakabe	CMCO, Senior Executive Officer & Director	1.4yrs	sin datos	0.0025% ¥ 3.2m
Mutsumi Kimura	Director	2yrs	sin datos	0.042% ¥ 53.7m
Masahide Tamaki	Full-Time Auditor	5yrs	sin datos	0.0050% ¥ 6.4m
Kazuko Kimura	Independent External Director	5yrs	sin datos	sin datos
Akihiko Kita	Full-Time Auditor	8yrs	sin datos	0.0013% ¥ 1.7m
Nobuko Kawashima	Independent External Director	8yrs	sin datos	sin datos
Yasuo Himeiwa	External Auditor	8yrs	sin datos	sin datos
Noriomi Matsumura	Independent External Director	4yrs	sin datos	sin datos

5.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 4974 se considera experimentada (5.3 años de antigüedad promedio).

Takara Bio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Less than half of directors are independent

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Consensus EPS estimates fall by 30%

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024

Consensus EPS estimates fall by 56%

Price target decreased by 17% to JP¥1,600

Upcoming dividend of JP¥17.00 per share

Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD)

Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 29%, revenue downgraded

Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 15%

Price target decreased by 17% to JP¥1,933

Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023

Takara Bio Inc. to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥42.00 per share at 2.3% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023

Price target decreased to JP¥2,250

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥2,400

Takara Bio Inc. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥2,515

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Takara Bio Inc. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥30.00 per share

Consensus revenue estimates increase by 16%

Price target decreased to JP¥2,742

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥2,792

Price target decreased to JP¥3,012

Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021)

Consensus EPS estimates increase to JP¥91.00

First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021)

Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Takara Bio Inc. to Report Fiscal Year 2021 Results on May 13, 2021

Analysts increase EPS estimates to JP¥53.65

Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020)

New 90-day high: JP¥3,045

New 90-day low: JP¥2,752

Takara Bio Inc. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: JP¥3,020

Takara Bio Inc. to Report Q2, 2021 Results on Nov 10, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta